Tissue Regenix (TRX) Stock Statistics & Valuation Metrics

Tissue Regenix has a market cap or net worth of £20.66M. The enterprise value is 48.99M.

Tissue Regenix has 71,395,640 shares outstanding. The number of shares has decreased by -2.65% in one year.

Tissue Regenix’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is 1.33%.

The current PE Ratio of Tissue Regenix is ―. Tissue Regenix’s PEG ratio is ―.

In the last 12 months, Tissue Regenix had revenue of 28.65M and earned -713.00K in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -1.33K and capital expenditures -360.11K, giving a free cash flow of -361.44K billion.

Tissue Regenix pays an annual dividend of ―, resulting in a dividend yield of ―

Tissue Regenix upcoming earnings date is Sep 3, 2025, TBA (Confirmed).

Tissue Regenix as a current ratio of 3.46, with Debt / Equity ratio of 35.10%

In the past 12 months, Tissue Regenix has paid 289.00K in taxes.

Tissue Regenix EV to EBITDA ratio is 45.16, with an EV/FCF ratio of -10.80.

Tissue Regenix has £3.46M in cash and marketable securities with £10.47M in debt, giving a net cash position of £7.01M billion.

Gross margin is 47.55%, with operating margin of 1.22%, and net profit margin of -2.49%.

The average price target for Tissue Regenix is £35.00, which is 11.43% higher than the current price. The consensus rating is Hold